|
15 Companies |
|
13 Products |
|
13 Products |
|
12 Mechanisms of Action |
|
0 Trials |
|
107 News |
|
| 123» |
- | Trial completion, Trial completion date: The EPIC Observational Study (clinicaltrials.gov) - Feb 1, 2019
P=N/A, N=1248, Completed, Sponsor: CF Therapeutics Development Network Coordinating Center
Active, not recruiting --> Completed | Trial completion date: Mar 2019 --> Dec 2018
- | SS1(dsFv)-PE38 / AstraZeneca
Trial termination: SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma (clinicaltrials.gov) - Aug 3, 2018
P1, N=24, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Mar 2019 --> Dec 2018 Completed --> Terminated
- | murepavadin (POL7080) / Spexis
Trial completion: Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia (clinicaltrials.gov) - Nov 28, 2017
P2, N=25, Completed, Sponsor: Polyphor Ltd.
Completed --> Terminated Terminated --> Completed
- | Trial initiation date: Clinical Trials to Reduce the Risk of Antimicrobial Resistance (clinicaltrials.gov) - Sep 29, 2017
P2, N=43, Terminated, Sponsor: University of Florida
Terminated --> Completed Initiation date: Jan 2013 --> Sep 2010
- | Trial completion: Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients (clinicaltrials.gov) - Jul 6, 2017
P3, N=164, Completed, Sponsor: Mukoviszidose Institut gGmbH
Initiation date: Jan 2013 --> Sep 2010 Active, not recruiting --> Completed
- | Trial completion: Tissue Collection From People With Cystic Fibrosis (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=100, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: ELIXIR: Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa (clinicaltrials.gov) - May 16, 2017
P4, N=17, Terminated, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated; Reason for termination was challenge with enrollment and recruitment. A significant decrease in the eligible patient population was main driver.
- | atorvastatin / Generic mfg.
Trial completion: Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa (clinicaltrials.gov) - May 3, 2017
P4, N=32, Completed, Sponsor: University of Edinburgh
A significant decrease in the eligible patient population was main driver. Active, not recruiting --> Completed
- | Trial primary completion date: Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients (clinicaltrials.gov) - Mar 23, 2017
P3, N=164, Active, not recruiting, Sponsor: Mukoviszidose Institut gGmbH
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Jun 2017
- | Enrollment closed, Enrollment change, Trial primary completion date: ELIXIR: Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa (clinicaltrials.gov) - Feb 13, 2017
P4, N=15, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2016 --> Jun 2017 Recruiting --> Active, not recruiting | N=35 --> 15 | Trial primary completion date: Jan 2017 --> May 2017
- murepavadin (POL7080) / Polyphor
Trial termination: Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis. (clinicaltrials.gov) - Feb 1, 2017
P2, N=20, Terminated, Sponsor: Polyphor Ltd.
Recruiting --> Active, not recruiting | N=35 --> 15 | Trial primary completion date: Jan 2017 --> May 2017 Completed --> Terminated
- ||| aztreonam / Generic mfg.
Trial completion: Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients (clinicaltrials.gov) - Jan 11, 2017
P=N/A, N=510, Completed, Sponsor: Gilead Sciences
Completed --> Terminated Active, not recruiting --> Completed
- SS1(dsFv)-PE38 / AstraZeneca
Trial completion: SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma (clinicaltrials.gov) - Oct 5, 2016
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change: Anti-Pseudomonas Immune Status and Dendritic Cell Preparation in Normal Individuals (clinicaltrials.gov) - Sep 21, 2016
P=N/A, N=8, Completed, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed Withdrawn --> Completed | N=60 --> 8
- Trial completion, Enrollment change, Trial primary completion date: PseudIgY: Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis (clinicaltrials.gov) - Sep 2, 2016
P1/2, N=14, Completed, Sponsor: Immunsystem AB
Withdrawn --> Completed | N=60 --> 8 Active, not recruiting --> Completed | N=20 --> 14 | Trial primary completion date: Dec 2018 --> Dec 2012
- murepavadin (POL7080) / Spexis
Trial termination, Trial primary completion date: Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia (clinicaltrials.gov) - Jun 19, 2016
P2, N=25, Terminated, Sponsor: Polyphor Ltd.
Active, not recruiting --> Completed | N=20 --> 14 | Trial primary completion date: Dec 2018 --> Dec 2012 Recruiting --> Terminated | Trial primary completion date: May 2016 --> Dec 2015
- ||||||| Trial completion: Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 (clinicaltrials.gov) - Apr 1, 2016
P2/3, N=803, Completed, Sponsor: Valneva Austria GmbH
Recruiting --> Terminated | Trial primary completion date: May 2016 --> Dec 2015 Active, not recruiting --> Completed
- Trial primary completion date: ELIXIR: Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa (clinicaltrials.gov) - Mar 5, 2016
P4, N=35, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Apr 2016 --> Jan 2017
- |||| Trial completion, Trial primary completion date: Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI) (clinicaltrials.gov) - Feb 24, 2016
P4, N=55, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2016 --> Jan 2017 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Oct 2015
- colistin sulphate / Generic mfg.
Trial completion, Trial primary completion date: Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036) (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=10, Completed, Sponsor: University of Pittsburgh
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Oct 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Aug 2015
- murepavadin (POL7080) / Spexis
Trial primary completion date: Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia (clinicaltrials.gov) - Nov 28, 2015
P2, N=25, Recruiting, Sponsor: Polyphor Ltd.
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Aug 2015 Trial primary completion date: Oct 2014 --> May 2016
- | murepavadin (POL7080) / Polyphor
Trial completion, Trial primary completion date: Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis. (clinicaltrials.gov) - Nov 28, 2015
P2, N=20, Completed, Sponsor: Polyphor Ltd.
Trial primary completion date: Oct 2014 --> May 2016 Recruiting --> Completed | Trial primary completion date: Sep 2014 --> Nov 2015
- | Trial completion: A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies (clinicaltrials.gov) - Nov 9, 2015
P=N/A, N=27, Completed, Sponsor: Indiana University
Recruiting --> Completed | Trial primary completion date: Sep 2014 --> Nov 2015 Enrolling by invitation --> Completed
- || aztreonam / Generic mfg.
Trial primary completion date: Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients (clinicaltrials.gov) - Sep 28, 2015
P=N/A, N=510, Active, not recruiting, Sponsor: Gilead Sciences
Enrolling by invitation --> Completed Trial primary completion date: Aug 2016 --> Nov 2016
- ||| Trial completion, Enrollment change: Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT) (clinicaltrials.gov) - Sep 28, 2015
P=N/A, N=156, Completed, Sponsor: T2 Biosystems
Trial primary completion date: Aug 2016 --> Nov 2016 Recruiting --> Completed | N=700 --> 156
- Enrollment change, Trial termination, Trial primary completion date: Clinical Trials to Reduce the Risk of Antimicrobial Resistance (clinicaltrials.gov) - Sep 18, 2015
P2, N=43, Terminated, Sponsor: University of Florida
Recruiting --> Completed | N=700 --> 156 N=480 --> 43 | Recruiting --> Terminated | Trial primary completion date: Jun 2018 --> Apr 2015; NIAID terminated the study due to low subject enrollment
- | Enrollment closed: Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients (clinicaltrials.gov) - Aug 12, 2015
P3, N=164, Active, not recruiting, Sponsor: Mukoviszidose Institut gGmbH
N=480 --> 43 | Recruiting --> Terminated | Trial primary completion date: Jun 2018 --> Apr 2015; NIAID terminated the study due to low subject enrollment Recruiting --> Active, not recruiting
- || Trial primary completion date: Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT) (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=700, Recruiting, Sponsor: T2 Biosystems
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2014 --> Aug 2015
- atorvastatin / Generic mfg.
Trial primary completion date: Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa (clinicaltrials.gov) - Jun 11, 2015
P4, N=32, Active, not recruiting, Sponsor: University of Edinburgh
Trial primary completion date: Aug 2014 --> Aug 2015 Trial primary completion date: Jun 2014 --> Jun 2015
- Trial completion, Enrollment change: The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis (clinicaltrials.gov) - Jun 2, 2015
P=N/A, N=53, Completed, Sponsor: Zafer Soultan
Trial primary completion date: Jun 2014 --> Jun 2015 Recruiting --> Completed | N=150 --> 53
- | Enrollment open, Trial initiation date, Trial primary completion date: ELIXIR: Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa (clinicaltrials.gov) - Apr 13, 2015
P4, N=35, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=150 --> 53 Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jan 2015 | Trial primary completion date: Dec 2015 --> Apr 2016
- ||||||| Cayston (aztreonam lysine) / Gilead
Trial completion, Enrollment change, Trial primary completion date: AZLI CAT: Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF (clinicaltrials.gov) - Apr 10, 2015
P3, N=90, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jan 2015 | Trial primary completion date: Dec 2015 --> Apr 2016 Active, not recruiting --> Completed | N=250 --> 90 | Trial primary completion date: Jun 2015 --> Jan 2015
- Enrollment change: Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life (clinicaltrials.gov) - Mar 18, 2015
P=N/A, N=0, Withdrawn, Sponsor: Tufts Medical Center
Active, not recruiting --> Completed | N=250 --> 90 | Trial primary completion date: Jun 2015 --> Jan 2015 N=10 --> 0
- Trial primary completion date: The EPIC Observational Study (clinicaltrials.gov) - Feb 26, 2015
P=N/A, N=1700, Active, not recruiting, Sponsor: CF Therapeutics Development Network Coordinating Center
N=10 --> 0 Trial primary completion date: Mar 2014 --> Dec 2018
- tobramycin inhalation / Generic mfg.
Enrollment change, Trial termination: Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles (clinicaltrials.gov) - Feb 6, 2015
P4, N=31, Terminated, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2014 --> Dec 2018 N=200 --> 31 | Recruiting --> Terminated
- Trial primary completion date: Clinical Trials to Reduce the Risk of Antimicrobial Resistance (clinicaltrials.gov) - Jan 26, 2015
P2, N=480, Recruiting, Sponsor: University of Florida
N=200 --> 31 | Recruiting --> Terminated Trial primary completion date: Dec 2017 --> Jun 2018
- |||| KB001-A / Humanigen
Trial completion: Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment (clinicaltrials.gov) - Jan 15, 2015
P2, N=182, Completed, Sponsor: KaloBios Pharmaceuticals
Trial primary completion date: Dec 2017 --> Jun 2018 Active, not recruiting --> Completed
- Arikace (amikacin liposome inhalation suspension) / Insmed
Enrollment change, Trial withdrawal: Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa (clinicaltrials.gov) - Jan 12, 2015
P3, N=0, Withdrawn, Sponsor: Insmed Incorporated
Active, not recruiting --> Completed N=300 --> 0 | Not yet recruiting --> Withdrawn
- colistin sulphate / Generic mfg.
Trial primary completion date: Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036) (clinicaltrials.gov) - Dec 9, 2014
P=N/A, N=10, Active, not recruiting, Sponsor: University of Pittsburgh
N=300 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Aug 2013 --> Dec 2014
- New P2 trial: RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot Study (clinicaltrials.gov) - Nov 20, 2014
P2, N=12, Completed, Sponsor: University Hospital Southampton NHS Foundation Trust.
- || Trial primary completion date: Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI) (clinicaltrials.gov) - Nov 5, 2014
P4, N=67, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2013 --> Dec 2014 Trial primary completion date: Dec 2014 --> Jun 2015
- fosfomycin tromethamine / Generic mfg.
Trial completion: Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol (clinicaltrials.gov) - Nov 3, 2014
P1, N=30, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2014 --> Jun 2015 Recruiting --> Completed
- | New P4 trial: ELIXIR: Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa (clinicaltrials.gov) - Sep 28, 2014
P4, N=35, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||||||| piperacillin sodium/tazobactam sodium / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa (clinicaltrials.gov) - Sep 22, 2014
P3, N=76, Completed, Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Recruiting --> Completed Recruiting --> Completed | N=400 --> 76 | Trial primary completion date: Oct 2012 --> Jan 2014
- Trial primary completion date: PseudIgY: Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis (clinicaltrials.gov) - Sep 5, 2014
P1/2, N=20, Active, not recruiting, Sponsor: Immunsystem AB
Recruiting --> Completed | N=400 --> 76 | Trial primary completion date: Oct 2012 --> Jan 2014 Trial primary completion date: Dec 2014 --> Dec 2018
- Trial primary completion date: Clinical Trials to Reduce the Risk of Antimicrobial Resistance (clinicaltrials.gov) - Sep 5, 2014
P2, N=480, Recruiting, Sponsor: University of Florida
Trial primary completion date: Dec 2014 --> Dec 2018 Trial primary completion date: Sep 2016 --> Dec 2017
- fosfomycin tromethamine / Generic mfg.
Enrollment open: Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol (clinicaltrials.gov) - Aug 19, 2014
P1, N=30, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Sep 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- Enrollment change: VOCCF: Volatile Organic Compounds in Cystic Fibrosis (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=24, Completed, Sponsor: Landon Pediatric Foundation
Not yet recruiting --> Recruiting N=75 --> 24
- ||| KB001-A / Humanigen
Enrollment closed: Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment (clinicaltrials.gov) - Aug 12, 2014
P2, N=180, Active, not recruiting, Sponsor: KaloBios Pharmaceuticals
N=75 --> 24 Recruiting --> Active, not recruiting
- fosfomycin tromethamine / Generic mfg.
New P1 trial: Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol (clinicaltrials.gov) - Jul 1, 2014
P1, N=30, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)